Lupin Gets USFDA Nod for Anti-Influenza Drug | CORPORATE ETHOS

Lupin Gets USFDA Nod for Anti-Influenza Drug

By: | January 10, 2018
lupin

Jan 10: Drug maker Lupin Ltd on Wednesday announced that it has received final approval for its Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) from the United States Food and Drug Administration (USFDA) to market a generic version of Hoffman-La Roche, Inc.’s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg.

“Lupin’s Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are the AB rated generic equivalent of Hoffman-La Roche, Inc.’s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg,” the company said.

Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.

The product had annual sales of approximately $467.8 million in the US, according to IMS MAT October 2017 data.

Lupin shares surged more than 1% to touch a new one-month high of Rs 932.40 intraday today on BSE after the news came in. At 2.07 pm, the Rs 2 face value shares were trading at Rs 928.95, up 0.88% from the previous closing of Rs 920.85.